Evidence map›Paper›PMID 42170754›Full record

ReviewBioMed research international2026

Anti-TNF Drug-Induced Sarcoidosis in Inflammatory Bowel Diseases: Multicentric Case Series and Literature Review.

Patrick Bez, Zlata Chkolnaia, Annalisa Aratari, Marta Ascolani, Péter Bacsur, Andreas Blesl, Philippe Seksik, Sara Nikolic, Savarino Edoardo V, Marcello Rattazzi and 2 more

Abstract readReviewMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Review in BioMed research international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Patrick BezRare Diseases Referral Center, Internal Medicine 1, Ca' Foncello Hospital, AULSS2 Marca Trevigiana, Treviso, Italy.
Zlata ChkolnaiaGastroenterology Department, Sorbonne Université, INSERM, Centre de Recherche Saint-Antoine, CRSA, AP-HP Saint-Antoine Hospital, Paris, France, sorbonne-universites.fr.ORCID https://orcid.org/0009-0002-3222-0529
Annalisa AratariIBD UNIT, San Filippo Neri Hospital, Rome, Italy, sanfilipponeri.roma.it.ORCID https://orcid.org/0000-0001-8816-6950
Marta AscolaniGastroenterology Unit, Ca' Foncello University Hospital, Treviso, Italy.
Péter BacsurCenter for Gastroenterology, Albert Szent-Györgyi Medical School, University of Szeged, Szeged, Hungary, u-szeged.hu.ORCID https://orcid.org/0000-0002-8534-0068
Andreas BleslDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Medical University of Graz, Graz, Austria, medunigraz.at.
Philippe SeksikGastroenterology Department, Sorbonne Université, INSERM, Centre de Recherche Saint-Antoine, CRSA, AP-HP Saint-Antoine Hospital, Paris, France, sorbonne-universites.fr.
Sara NikolicDepartment of Gastroenterology, University Medical Center Maribor, Maribor, Slovenia, ukc-mb.si.
Savarino Edoardo VDepartment of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy, unipd.it.ORCID https://orcid.org/0000-0002-3187-2894
Marcello RattazziRare Diseases Referral Center, Internal Medicine 1, Ca' Foncello Hospital, AULSS2 Marca Trevigiana, Treviso, Italy.
Francesco CinettoRare Diseases Referral Center, Internal Medicine 1, Ca' Foncello Hospital, AULSS2 Marca Trevigiana, Treviso, Italy.
Carla FeliceRare Diseases Referral Center, Internal Medicine 1, Ca' Foncello Hospital, AULSS2 Marca Trevigiana, Treviso, Italy.ORCID https://orcid.org/0000-0001-6646-6231

Funding

CRUI-CAREUniversita degli Studi di Padova
6 · The paper itself

Abstract

introductionSarcoidosis is an inflammatory granulomatous condition and presents overlapping features with inflammatory bowel disease (IBD). Anti-TNF treatment has revolutionized the management of several conditions, including IBD and sarcoidosis. Yet, anti-TNF drugs have been associated with drug-induced sarcoidosis reaction (DISR).

methodsThis is a retrospective, international, multicentric case series, including IBD patients with anti-TNF-related DISR. A literature review was performed to identify previously published cases.

resultsNine new cases of anti-TNF-related DISR in IBD are described with a long follow-up (median 45 months). After literature review, a total of 26 cases were identified. The diagnosis required histological evidence of granulomas in involved organs in all patients. Most patients had a diagnosis of Crohn's disease (n = 19, 73.1%). The culprit drug was infliximab in 15 (57.7%) and adalimumab in 11 (42.3%). The median time to sarcoidosis development was 21 months. Compared to conventional sarcoidosis, extrathoracic involvement was more prevalent (n = 20, 76.7%). Management of DISR consisted of discontinuing anti-TNF treatment in 20 cases (76.9%) and providing specific treatment in 17 cases (65.4%), with favorable outcomes in all cases.

conclusionDespite its rarity, DISR may be challenging for IBD patients. Discontinuation of anti-TNF treatment is recommended, and specific treatment is required for moderate-to-severe cases.

Indexed as

Inflammatory Bowel DiseasesSarcoidosisTumor Necrosis Factor-alphaAdalimumabAdultFemaleHumansInfliximabMaleMiddle AgedRetrospective StudiesAdalimumabInfliximabTumor Necrosis Factor-alphaanti-TNFdrug-induced sarcoidosisinflammatory bowel diseaseinfliximabsarcoidosis

Identifiers

PMID42170754
PMCPMC13195438

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.